Interleukin-10 suppression of myeloid cell activation - A continuing puzzle

Immunology

Volumn 113, Issue 3, 2004, Pages 281-292

  Williams, Lynn M ^a   Ricchetti, Giuseppe ^a   Sarma, Usha ^a   Smallie, Timothy ^a   Foxwell, Brian M J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokines interleukins; Inflammation inflammatory mediators including eicosanoids; Signalling signal transduction

Indexed keywords

INTERLEUKIN 10; JANUS KINASE; JANUS KINASE 1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW CELL; CELL ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

CYTOKINES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-10; MYELOID CELLS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 8144226985     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01988.x     Document Type: Review

References (133)

1. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-95.'
2. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
3. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol Rev 2003; 55:241-69.
4. Hsu DH, de Waal Malefyt R, Fiorentino DF et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250:830-2.
5. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA 2000; 97:1695-700.
6. Gastl GA, Abrams JS, Nanus DM et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55:96-101.
7. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995; 155:2240-7.
8. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24:392-407.
9. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104:9-19.
10. Gallagher G, Dickensheets H, Eskdale J et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1:442-50.
11. Dumoutier L, Lejeune D, Colau D, Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/ IL-22. J Immunol 2001; 166:7090-5.
12. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11:2477-86.
13. Knappe A, Hor S, Wittmann S, Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol 2000; 74:3881-7.
14. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24:2699-705.
15. Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994; 13:47-54.
16. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96:2304-10.
17. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995; 25:394-8.
18. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151:1224-34.
19. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150:4754-65.
20. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81:2964-71.
21. Schandene L, Alonso-Vega C, Willems F et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994; 152:4368-74.
22. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182:68-79.
23. Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7.
24. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605-17.
25. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725-31.
26. Saeland S, Ouvert V, Moreau I, Banchereau J. Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med 1993; 178:113-20.
27. Roussel F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89:1890-3.
28. Burdin N, Van Kooten C, Galibert L, Abrams JS, Wijdenes J, Banchereau J, Rousset F. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995; 154:2533-44.
29. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181:839-44.
30. Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43:1790-1800.
31. Gerard C, Bruyns C, Marchant A et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-50.
32. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39:495-503.
33. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2003; 52:363-9.
34. Kolb H, Worz-Pagenstert U, Kleemann R, Rothe H, Rowsell P, Rastegar S, Scott FW. Insulin therapy of prediabetes suppresses TH1 associated gene expression in BB rat pancreas. Autoimmunity 1997; 26:1-6.
35. Cua DJ, Coffman RL, Stohlman SA. Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function. J Immunol 1996; 157:2830-6.
36. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 1999; 189:1005-10.
37. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy; a new therapeutic approach. J Clin Invest 1998; 101:783-94.
38. Fedorak RN, Gangl A, Elson CO et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473-82.
39. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24:629-39.
40. Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994; 152:1821-9.
41. Kotenko S, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 1997; 16:5894-903.
42. Spencer SD, Di Marco F, Hooley J et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998; 187:571-8.
43. Weite T, Zhang SS, Wang T et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA 2003; 100:1879-84.
44. Karaghiosoff M, Neubauer H, Lassnig C et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13:549-60.
45. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A 1993; 90:11267-71.
46. O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms, evidence for Stat3-dependent and -independent pathways. EMBO J 1998; 17:1006-18.
47. Riley JK, Takeda K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999; 274:16513-21.
48. Lai CF, Ripperger J, Morella KK et al. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem 1996; 271:13968-75.
49. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S. Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001; 276:2725-32.
50. Kotenko SV. The family of IL-10-related cytokines and their receptors; related, but to what extent? Cytokine Growth Factor Rev 2002; 13:223-40.
51. Xie MH, Aggarwal S, Ho WH et al. Interleukin (IL) -22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000; 275:31335-9.
52. Kotenko SV, Langer JA. Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 2004; 4:593-608.
53. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004; 76:314-21.
54. Sheikh F, Baurin VV, Lewis-Antes A et al. Cutting edge. IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol 2004; 172:2006-10.
55. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277:33676-82.
56. Hor S, Pirzer H, Dumoutier L et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 2004; 279:33343-51.
57. Dumoutier L, Van Roost E, Colau D, Renauld JC. Human interleukin-10- related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000; 97:10144-9.
58. Nagalakshmi ML, Murphy E, McClanahan T, de Waal Malefyt R. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol 2004; 4:577-92.
59. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004; 4:679-91.
60. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39:1332-42.
61. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 2001; 21:1047-53.
62. Usacheva A, Kotenko S, Witte MM, Colamonici OR. Two distinct domains within the N-terminal region of Janus kinase 1 interact with cytokine receptors. J Immunol 2002; 169:1302-8.
63. Usacheva A, Sandoval R, Domanski P, Kotenko SV, Nelms K, Goldsmith MA, Colamonici OR. Contribution of the Box I and Box 2 motifs of cytokine receptors to Jak1 association and activation. J Biol Chem 2002; 277:48220-6.
64. Ho AS, Wei SH, Mui AL, Miyajima A, Moore KW. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol Cell Biol 1995; 15:5043-53.
65. Gasche C, Grundtner P, Zwirn P et al. Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol 2003; 170:5578-82.
66. Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 1995; 155:1079-90.
67. Lamer A, David M, Feldman GM et al. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 1993; 261:1730-3.
68. Wehinger J, Gouilleux F, Groner B, Finke J, Mertelsmann R. Weber-Nordt RM. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 1996; 394:365-70.
69. Herrero C, Hu X, Li WP, Samuels S, Sharif MN, Kotenko S, Ivashkiv LB. Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol 2003; 171:5034-41.
70. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443-50.
71. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, Heinrich PC, Muller-Newen G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003; 170:3263-72.
72. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004; 172:567-76.
73. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003; 4:546-50.
74. Croker BA, Krebs DL, Zhang JG et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003; 4:540-5.
75. Yasukawa H, Ohishi M, Mori H et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003; 4:551-6.
76. Kontoyiannis D, Kotlyarov A, Carballo E et al. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J 2001; 20:3760-70.
77. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-22.
78. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes. an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
79. Denys A, Udalova IA, Smith C, Williams LM, Campbell J, Andrews C, Kwaitkowski D, Foxwell BM. Evidence for a dual mechanism for IL-10 suppression of TNF-alpha production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-kappa B in primary human macrophages. J Immunol 2002; 168:4837-45.
80. Pajkrt D, Camoglio L, Tiel-van Buul MC et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol 1997; 158:3971-7.
81. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994; 10:405-55.
82. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-83.
83. Finco TS, Baldwin AS. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995; 3:263-72.
84. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725-34.
85. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 1990; 171:35-47.
86. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998; 273:21178-86.
87. Kuprash DV, Udalova IA, Turetskaya RL, Kwiatkowski D, Rice NR, Nedospasov SA. Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol 1999; 162:4045.
88. Tak PP, Firestein GS. NF-kappaB; a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11.
89. Bondeson J, Browne KA, Brennan FM, Foxwell BM, Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent. J Immunol 1999; 162:2939-45.
90. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270:9558-63.
91. Shames BD, Selzman CH, Meldrum DR, Pulido EJ, Barton HA, Meng X, Harken AH, McIntyre RC Jr. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock 1998; 10:389-94.
92. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274:31868-74.
93. Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS, Tisch R. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and I{kappa} B kinase activity. Blood 2004; 10:1100-9.
94. Zhou L, Nazarian AA, Smale ST. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 2004; 24:2385-96.
95. Clarke CJ, Hales A, Hunt A, Foxwell BM. IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol 1998; 28:1719-26.
96. Geng Y, Zhang B, Lotz M. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J Immunol 1993; 151:6692-700.
97. Beaty CD, Franklin TL, Uehara Y, Wilson CB. Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal transduction. Eur J Immunol 1994; 24:1278-84.
98. Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BMJ, Brennan FM. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-α: Role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 1998; 160:920-8.
99. Geng Y, Gulbins E, Altman A. Lotz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci USA 1994; 91:8602-6.
100. Lee JC, Laydon JT, McDonnell PC et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:739-46.
101. Clark AR, Dean JL, Saklatvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003; 546:37-44.
102. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor, a predictive genetic model of arthritis. EMBO J 1991; 10:4025-31.
103. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10:387-88.
104. Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 1999; 19:563-73.
105. Biswas R, Datta S, Gupta JD, Novotny M, Tebo J, Hamilton TA. Regulation of chemokine mRNA stability by lipopolysaccharide and IL-10. J Immunol 2003; 170:6202-8.
106. Kishore R, Tebo JM, Kolosov M, Hamilton TA. Cutting edge, clustered AU-rich elements are the target of IL-10-mediated mRNA destabilization in mouse macrophages. J Immunol 1999; 162:2457-61.
107. Rodig SJ, Meraz MA, White JM et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93:373-83.
108. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10:39-49.
109. Maritano D, Sugrue ML, Tininini S et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 2004; 5:401-9.
110. Crawley JB, Williams LM, Mander T, Brennan FM, Foxwell BM. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70, S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J Biol Chem 1996; 271:16357-62.
111. Zhou JH, Broussard SR, Strle K, Freund GG, Johnson RW, Dantzer R, Kelley KW. IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 3′-kinase. J Immunol 2001; 167:4436-42.
112. Pahan K, Khan M, Singh I. Interleukin-10 and interleukin-13 inhibit proinflammatory cytokine-induced ceramide production through the activation of phosphatidylinositol 3-kinase. J Neurochem 2000; 75:576-82.
113. Herrera-Velit P, Reiner NE. Bacterial lipopolysaccharide induces the association and coordinate activation of p53/561yn and phosphatidylinositol 3-kinase in human monocytes. J Immunol 1996; 156:1157-65.
114. Guha M, Mackman N. The Phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccheride activation of signalling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277:32124-32.
115. Williams DL, Li C, Ha T et al. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 2004; 172:449-56.
116. Aste-Amezaga M, Ma X, Sartori A, Trinchieri G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol 1998; 160:5936-44.
117. Bogdan C, Paik J, Vodovotz Y, Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin 10. J Biol Chem 1992; 267:23301-8.
118. Yano S, Yanagawa H, Nishioka Y, Mukaida N, Matsushima K. Sone S. T helper 2 cytokines differently regulate monocyte chemoattractant protein-1 production by human peripheral blood monocytes and alveolar macrophages. J Immunol 1996; 157:2660-5.
119. Sozzani S, Ghezzi S, Iannolo G et al. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 1998; 187:439-44.
120. Ritter M, Buechler C, Langmann T, Orso E, Klucken J, Schmitz G. The scavenger receptor CD163: regulation, promoter structure and genomic organization. Pathobiology 1999; 67:257-61.
121. Dickensheets HL, Freeman SL, Smith MF, Donnelly RP. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 1997; 90:4162-71.
122. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Lamer AC, Finbloom DS. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999; 93:1456-63.
123. Williams L, Jarai G, Smith A, Finan P. IL-10 expression profiling in human monocytes. J Leukoc Biol 2002; 72:800-9.
124. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002; 169:2253-63.
125. Jung M, Sabat R, Kratzschmar J et al. Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol 2004; 34:481-493
126. Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, Takeda K, Akira S. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003; 102:4123-9.
127. Perrier P, Martinez FO, Locati M et al. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13. J Immunol 2004; 172:7031-42.
128. Colonna M, Nakajima H, Navarro F, Lopez-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol 1999; 66:375-81.
129. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, Mancini D, Suciu-Foca N. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11:245-58.
130. Chang CC, Ciubotariu R, Manavalan JS et al. Tolerization of dendritic cells by T (S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3:237-43.
131. Lee TS, Chau LY. Heme oxygenase-1 mediates the antiinflammatory effect of IL-10 in mice. Nat Med 2002; 8:240-6.
132. Petit-Bertron AF, Fitting C, Cavaillon JM, Adib-Conquy M. Adherence influences monocyte responsiveness to interleukin-10. J Leukoc Biol 2003; 73:145-54.
133. Ricchetti G, Williams LM, Foxwell BM. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. J Leukoc Biol 2004; 76:719-26.